Psyence Biomedical Ltd. (NasdaqCM: PBM)
Health Care · Biotechnology · CA
$4.40
+26.44% today · -83.1% 1Y
Psyence Biomedical Ltd. (NasdaqCM: PBM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $13.27M and employs 12 people.
Over the last twelve months the share price has lost 83.1%, trading between 1.92 and 34.63.
Tweenvest scores Psyence Biomedical Ltd. across four factors: quality 27/100. Its strongest factor is quality.
PBM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.27M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -12.56
- Dividend yield
- —
- Beta (5Y)
- 1.67
- 52-week high
- $34.63
- 52-week low
- $1.92
- Avg volume (3M)
- —
- Shares outstanding
- 3.81M
- Employees
- 12
- Next earnings
- —
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
- ISIN
- CA74449F4078
- Listed since
- Dec 10, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.26 | -1.70% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.02 | -0.73% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.48 | -0.87% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.02 | -1.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.08 | -1.02% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $150.71 | -5.11% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.